0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover3447.40%IV81.74%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.0323Delta0.0033Gamma14.60Leverage Ratio-0.7267Theta0.0000Rho-0.47Eff Leverage0.0005Vega
Inovio Pharmaceuticals Stock Discussion
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet